nPulse Cardiac Catheter for AF ablation to be highlighted in late-breaking clinical science session and in a live case transmission

HAYWARD, Calif.--(BUSINESS WIRE)--Feb. 3, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced its nPulse technology will be featured in a late-breaking science session and a live case transmission featuring the nPulse Cardiac Catheter integrated with Abbott’s EnSiteX™ 3D Mapping System at the 31^st Annual AF Symposium 2026 meeting, being held February 5-7 in Boston, Massachusetts.

“We are pleased to share 6-month and 12-month follow-up data from our Cardiac Catheter Human Feasibility Study in Europe. The data are expected to highlight the disruptive potential of nanosecond PFA for the treatment of atrial fibrillation,” said Paul LaViolette, Co-Chairman of Pulse Biosciences’ Board of Directors. “This is an exciting milestone for Pulse Biosciences, and I would like to thank our team, the clinicians and the patients for their contributions to this seminal data set. We look forward to engaging with the entire clinical community at this important meeting.”

Key nPulse Technology Scientific Programming

Thursday, February 5 ^th

• 5:00-7:00pm, Vivek Reddy, MD – Late Breaking Clinical Science Session
• Title: Nanosecond Pulse Field Ablation Using a Compliant Circular Catheter to Treat Atrial Fibrillation: A Multicenter Experience
• Review of the first 150 patients treated including 6- and 12-month follow-up for a subset of patients in a feasibility study with the nPulse Cardiac Catheter at three European centers.

Friday, February 6 ^th and Saturday, February 7^th

• Poster Presentation
• Title: Nanosecond Pulses Generate Deeper Cardiac Lesions Compared to Microsecond Pulses at Matched Energy
• Presentation of a preclinical study showing that cardiac tissue ablations using nanosecond pulsed electric fields produced significantly deeper lesions compared with microsecond pulses utilizing the same electrode and with matched energy

Saturday, February 7 ^th

• 7:30-9:30am, Petr Neuzil, MD, PhD, Jan Petru, MD, and Moritoshi Funasako MD, PhD (Na Homolce Hospital, Prague, Czech Republic) – Live Case Transmission
• Title: Enhanced AF Workflow with Nanosecond Pulsed Field Ablation and 360 Degree Conforming Catheter
• Live case broadcast from Na Homolce Hospital in Prague, CZ. The live case will highlight the nPulse Cardiac Catheter’s workflow efficiency for pulmonary vein isolation, and 3D mapping and navigation integration with Abbott’s EnSiteX™ 3D Mapping System as part of a 3D mapping workflow

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation.

Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company’s nsPFA technology and nPulse System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning early clinical successes and whether they are predictive of the safety and effectiveness of any medical device, such as the nPulse Cardiac Catheter, statements concerning disruptive market opportunities, customer adoption and future use of the nPulse System to address a range of conditions such as atrial fibrillation, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260203979934/en/

Investors:
Pulse Biosciences, Inc.
Jon Skinner, CFO
IR@pulsebiosciences.com

Or

Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com

Source: Pulse Biosciences, Inc.